Showing 1 - 6 results of 6 for search 'Hany Elmaraghy', query time: 0.05s Refine Results
  1. 1
    Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale

    Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale by Alissa Rams, Jessica Baldasaro, Laurine Bunod, Laure Delbecque, Sara Strzok, Juliette Meunier, Hany ElMaraghy, Luna Sun, Evangeline Pierce

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

    Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials by Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

    The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis by Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

    Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials by Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  5. 5
    Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis

    Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis by Peter A. Lio, April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, Sherry Chen, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Zach Dawson, Tiago Torres

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  6. 6
    Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

    Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp

    Published 2020
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: